Amphastar's Q2 2024 revenue grew 25% YOY to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Find out ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Calling the decision not to disclose the genetic results “certainly troubling” and “ethically fraught,” George Perry, editor ...

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road that'll pave the way for Eli Lilly (NYSE: LLY) to ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...